24.07.2025 • News • AstraZeneca • investment • Pharma

AstraZeneca to Invest $50 Billion in US Manufacturing

AstraZeneca recently announced $50 billion of investment in the US by 2030. This investment is expected to create tens of thousands of new, highly skilled jobs nationwide.

AstraZeneca building — The cornerstone of the investment is a proposed new multi-billion dollar drug substance manufacturing center focused on chronic diseases in Virginia, the Company’s largest single investment in a facility to date.
© AstraZeneca

The highlight of this investment is a new multi-billion-dollar US manufacturing facility that will produce drug substances for the company’s weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9, and combination small molecule products. The new state-of-the-art centre will produce small molecules, peptides, and oligonucleotides. This multi-billion-dollar capital investment is in addition to the $3.5 billion announced in November 2024.

The drug substance facility, planned for construction in Virginia, would be AstraZeneca’s largest single manufacturing investment in the world. The facility will leverage AI, automation, and data analytics to optimise production.

The $50 billion investment across the company's R&D and manufacturing footprint in the US over the next five years also includes:

Expansion of its R&D facility in Gaithersburg, Maryland
State-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts
Next-generation manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California
Continuous manufacturing expansion in Mount Vernon, Indiana
Specialty manufacturing expansion in Coppell, Texas
New sites to supply clinical trials

Collectively, these investments will help deliver AstraZeneca’s ambition of reaching $80 billion in Total Revenue by 2030, of which it expects 50% would be generated in the US.

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “Today’s announcement underpins our belief in America’s innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally. It will also support our ambition to reach $80 billion in revenue by 2030. I look forward to partnering with Governor Youngkin and his team to work on our largest single manufacturing investment ever. It reflects the Commonwealth of Virginia’s desire to create highly skilled jobs in science and technology, and will strengthen the country’s domestic supply chain for medicines.”